Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | S100A4 | P26447 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1120113 | 1.00 | PPARG (0.44) | PPARGNFE2L2LMNAALDH1A1MAPT | |
| SCHEMBL3730162 | 0.84 | PPARG (0.57) | PPARGNFE2L2LMNAALDH1A1MAPT | |
| SCHEMBL19155588 | 0.84 | PPARG (0.57) | PPARGNFE2L2LMNAALDH1A1MAPT | |
| SCHEMBL587895 | 0.84 | PPARG (0.57) | PPARGNFE2L2LMNAALDH1A1MAPT | |
| SCHEMBL1194569 | 0.84 | PPARG (0.57) | PPARGNFE2L2LMNAALDH1A1MAPT | |
| SCHEMBL15845143 | 0.82 | PPARG (0.55) | PPARGNFE2L2LMNAALDH1A1KMT2A | |
| SCHEMBL21647828 | 0.82 | PPARG (0.55) | PPARGNFE2L2LMNAALDH1A1KMT2A | |
| Cinnamonitrile SCHEMBL996307 | 0.75 | KDM4E (0.54) | NFE2L2LMNAALDH1A1MAPTKMT2A | |
| Cinnamonitrile SCHEMBL23599 | 0.75 | KDM4E (0.54) | NFE2L2LMNAALDH1A1MAPTKMT2A | |
| Cinnamonitrile SCHEMBL23933 | 0.75 | KDM4E (0.54) | NFE2L2LMNAALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011130395-A1 | INHIBITORS OF FLIP TO TREAT CANCER | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2011-10-20 | — | — | WO | disclosed |
| US-20110251135-A1 | INHIBITORS OF PERITONEAL SEEDING OF CANCER CELLS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2011-10-13 | — | — | US | disclosed |
| US-7989495-B2 | 3-Sulfonyl propenenitriles, e.g., BAY 11-7085 (3-(t-butylphenylsulfonyl)-2-propenenitrile; promoting apoptosis and inhibiting readhesion of cancer cells; antimetastasis agents, particularly for hepatic, parietal or peritoneal area; inhibiting tumorigenesis; antiproliferative agents (not for myeloma) | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2011-08-02 | — | — | US | disclosed |
| EP-2281077-A2 | INHIBITORS OF PERITONEAL SEEDING OF CANCER CELLS | University of Utah Research Foundation (US) | 2011-02-09 | — | — | EP | disclosed |
| WO-2009124272-A2 | INHIBITORS OF PERITONEAL SEEDING OF CANCER CELLS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20050124590-A1 | Compositions and methods for inhibiting nf-kappab mediated tumorigenicity and adhesion dependent survival of cancer cells | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-09 | — | — | US | disclosed |
| WO-2003072038-A2 | COMPOSITIONS AND METHODS FOR INHIBITING NF-κB MEDIATED TUMORIGENICITY AND ADHESION-DEPENDENT SURVIVAL OF CANCER CELLS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124590-A1 | Compositions and methods for inhibiting nf-kappab mediated tumorigenicity and adhesion dependent survival of cancer cells | NFKBIA, RELA, NFKB1 | PPARG 4273/4885NFE2L2 242/4885LMNA 1462/4885 |
| US-20110251135-A1 | INHIBITORS OF PERITONEAL SEEDING OF CANCER CELLS | NFKBIA, IKBKB, RELA | PPARG 4448/4885NFE2L2 179/4885LMNA 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.